Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002130 · ClinicalTrials.gov registry record · NA
A Long-Term, Follow-On Safety Study of Four Doses of OPC-8212 (Vesnarinone) in HIV-Infected Persons
A NA study, sponsored by Otsuka America Pharmaceutical.
- Completed
- Registry status
- NA
- Development phase
NCT00002130: Completed NA study, sponsored by Otsuka America Pharmaceutical.
NCT00002130 is a NA study that has completed, run by Otsuka America Pharmaceutical. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002130, a NA study, has completed, sponsored by Otsuka America Pharmaceutical.
- COMPLETED
- Registry status
- NA
- Development phase
Study Summary
To examine the continued safety and tolerability of four doses of vesnarinone in HIV-infected patients who have completed a short-term study (less than 12 months on continuous treatment) of the drug.
Interventions
- DRUG Vesnarinone
Trial Details
| Field | Value |
|---|---|
| Phase | NA |
What the finished NCT00002130 record still lists
NCT00002130 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which Vesnarinone is the first listed.
NCT00002130 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002130 about?
NCT00002130 is a clinical study titled "A Long-Term, Follow-On Safety Study of Four Doses of OPC-8212 (Vesnarinone) in HIV-Infected Persons". To examine the continued safety and tolerability of four doses of vesnarinone in HIV-infected patients who have completed a short-term study (less than 12 months on continuous treatment) of the drug.
What is the current status of trial NCT00002130?
This trial is currently completed. It is a NA study.
What interventions are being tested in trial NCT00002130?
The interventions under investigation include: Vesnarinone (DRUG).
Who is sponsoring clinical trial NCT00002130?
This trial is sponsored by Otsuka America Pharmaceutical, which has 10 total clinical trials registered on ClinicalTrials.gov.